AB004. Peyronie’s disease: 2017 update
Plenary Session

AB004. Peyronie’s disease: 2017 update

Tom F. Lue

University of California, San Francisco, USA


Abstract: Peyronie’s disease (PD) is characterized by a symptom complex of penile plaque (fibrotic nodule), deformity (bending, indentation or shortening), painful erection and erectile dysfunction. The prevalence in China is unknown. The natural history of the disease is reported to be progressive as 45% of the patient experience worsening of the symptoms 1 year after diagnosis. However, the prevalence and disease characteristics in Chinese are unknown. Many treatment options have been used for PD with varying degrees of success. In this article, we review and summarize the current literature pertaining to all pharmacotherapies (oral, intralesional, iontophoresis, and topical) and minimally invasive treatments available for PD (vacuum, traction device, shock wave therapy, and radiation treatment). Additionally, we discuss emerging therapies for PD that are still in pre-clinical development, including stem cell therapy.

Keywords: Peyronie’s disease (PD); erectile dysfunction; shock wave therapy; stem cell therapy


doi: 10.21037/tau.2017.s004


Cite this abstract as: Lue TF. Peyronie’s disease: 2017 update. Transl Androl Urol 2017;6(Suppl 3):AB004. doi: 10.21037/tau.2017.s004